ELEVECTA
LIVE

Serial Number

79272524

Owner

CEVEC Pharmaceuticals GmbH

Attorney

Dyan M. House

Filing Date

Aug 12, 2019

Add to watchlist:

No watchlists yet
View on USPTO

ELEVECTA Trademark

Serial Number: 79272524 • Registration: 6110170

ELEVECTA is a trademark filed by CEVEC Pharmaceuticals GmbH on August 12, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

CEVEC Pharmaceuticals GmbH (7 trademarks)

Gottfried-Hagen-Strasse 62
51105 Köln , DE

Entity Type: 03

Trademark Details

Filing Date

August 12, 2019

Registration Date

July 28, 2020

Published for Opposition

May 12, 2020

Goods & Services

Medicines for the treatment of leukemia, of solid and liquid cancer, of monogenic diseases, of neurological disorders, of neuromuscular disorders, of metabolic disorders, and of viral and infectious diseases; pharmaceutical and veterinary products, preparations and reagents for the treatment of leukemia, of solid and liquid cancer, of monogenic diseases, of neurological disorders, of neuromuscular disorders, of metabolic disorders, and of viral and infectious diseases; chemical, biological and biochemical substances, preparations and reagents for medical and veterinary purposes, namely, for the treatment of leukemia, of solid and liquid cancer, of monogenic diseases, of neurological disorders, of neuromuscular disorders, of metabolic disorders, and of viral and infectious diseases; diagnostic and analytical preparations for medical and veterinary purposes; cultures of microorganisms and viruses for medical or veterinary purposes, in particular adeno-associated viruses; proteins, polypeptides, nucleotides, nucleic acids, eukaryotic cell lines and eukaryotic cells, in particular transfected and/or selected eukaryotic cell lines and eukaryotic cells for medical or veterinary purposes, namely, for the treatment of leukemia, of solid and liquid cancer, of monogenic diseases, of neurological disorders, of neuromuscular disorders, of metabolic disorders, and of viral and infectious diseases; expression systems in the nature of microorganisms, insect cells, and mammalian cells, for manufacturing stable or transient transfected eukaryotic cell lines and eukaryotic cells, for medical and veterinary purposes; expression systems in the nature of microorganisms, insect cells, and mammalian cells, for manufacturing viral vectors, in particular vectors of adeno-associated viruses, for medical, veterinary and medical diagnostic purposes

Scientific and industrial research, in particular in the field of medicine, pharmacy, molecular biology, biotechnology and genetics; research and development of drugs, diagnostic and analytical preparations, therapy procedures, and expression systems in the nature of microorganisms, insect cells, and mammalian cells; scientific, technical and industrial research consultancy, in particular in the field of medicine, pharmacy, molecular biology, biotechnology and genetics; scientific laboratory services, namely, cultivation, extraction, optimization, synthesizing and modifying of eukaryotic cell lines, eukaryotic cells, in particular transfecting and selecting of eukaryotic cells and eukaryotic cell lines with a nucleic acid, in particular a plasmid, viruses, in particular adeno-associated viruses, viral vectors, in particular vectors of adeno-associated viruses, polypeptides, proteins, nucleotides, nucleic acids, for third parties for scientific, research, laboratory, development, industrial and commercial purposes, in particular for use in the field of medicine, pharmacy, molecular biology, biotechnology and genetics; scientific analysis, research and development in the nature of analysis and selection of transfected eukaryotic cells and eukaryotic cell lines and viral vectors, in particular vectors of adeno-associated viruses, for third parties for scientific, research, laboratory, development, industrial and commercial purposes, in particular for use in the field of medicine, pharmacy, molecular biology, biotechnology and genetics

Chemical, biological and biochemical reagents for scientific, research, laboratory, industrial and commercial purposes; Chemical, biological and biochemical substances and preparations for scientific, research and laboratory use; chemical, biological and biochemical substances, preparations and reagents for research use in characterizing diseases; chemical, biological and biochemical substances, preparations and reagents for scientific and medical research and drug development; chemical, biological and biochemical substances, preparations and reagents for manufacturing drugs and pharmaceuticals; cultures of microorganisms and viruses, other than for medical or veterinary purposes, in particular adeno-associated viruses; proteins, polypeptides, nucleotides, nucleic acids, eukaryotic cell lines and eukaryotic cells, in particular transfected and/or selected eukaryotic cell lines and eukaryotic cells, other than for medical or veterinary purposes; expression systems in the nature of microorganisms, insect cells, and mammalian cells, for manufacturing stable or transient transfected eukaryotic cell lines and eukaryotic cells, other than for medical or veterinary purposes; expression systems in the nature of microorganisms, insect cells, and mammalian cells for scientific, research, laboratory, industrial and commercial purposes, namely, for manufacturing viral vectors, in particular vectors of adeno-associated viruses

Filing History

NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Jun 12, 2026 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Jun 12, 2026 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
May 18, 2026 APRE
TEAS SECTION 71 & 15 RECEIVED
Jan 29, 2026 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jul 28, 2025 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Oct 18, 2024 NREP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 9, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Aug 9, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 9, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 9, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 9, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 9, 2024 COAR
NEW REPRESENTATIVE AT IB RECEIVED
Nov 19, 2023 NREP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 21, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Aug 21, 2023 ECDR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Aug 21, 2023 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 21, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 21, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 21, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 21, 2023 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 13, 2021 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jul 13, 2021 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 13, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 13, 2021 REAP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 11, 2021 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jun 11, 2021 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 11, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 11, 2021 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 6, 2020 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 17, 2020 FICS
FINAL DISPOSITION PROCESSED
Nov 16, 2020 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 28, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 28, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 12, 2020 NPUB
PUBLISHED FOR OPPOSITION
May 12, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 22, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 18, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 17, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 17, 2020 TROA
REFUSAL PROCESSED BY IB
Jan 24, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 3, 2020 RFCS
REFUSAL PROCESSED BY MPU
Jan 2, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 4, 2019 RFCR
NON-FINAL ACTION WRITTEN
Dec 3, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
Nov 29, 2019 MAFR
ASSIGNED TO EXAMINER
Nov 26, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 25, 2019 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 21, 2019 REPR